American Society of Hematology

Hematologic Drug Shortage Information


Updated on: March 26, 2014

ASH continues to work with Congress, federal agencies, and other stakeholders to ensure continued access to safe and effective hematologic drugs.

New Updates on Hematologic Drug Shortages

FDA Requests Suspension of Marketing and Sales of Iclusig (ponatinib) –FDA has asked the manufacturer of the leukemia chemotherapy drug Iclusig (ponatinib) to suspend marketing and sales of Iclusig because of the risk of life-threatening blood clots and severe narrowing of blood vessels. Patients currently receiving Iclusig should discuss with their health care professionals the risks and benefits of continuing treatment with the drug. The drug manufacturer, Ariad Pharmaceuticals, has agreed to FDA's request to suspend marketing and sales of Iclusig while the FDA continues to evaluate the safety of the drug.back to top

Current Hematologic Drug Shortages

back to top

Recently Resolved Hematologic Drug Shortages

  • Aminocaproic Acid (Amicar)
  • Metoclopramide Injection (Reglan)
back to top

Additional Resources

back to top

ASH's Comments to Congress and the U.S. Food and Drug Administration

back to top

Media Coverage of Drug Shortages

back to top